ClinicalTrials.gg
RecruitingNCT05757817LAMBEAU STEPAUpdated Nov 18, 2026

Evaluation of the Benefit of a New Surgical Procedure According to IDEAL Recommendations for ORL Cancer Patients: the External Pudendal Flap Used as a New Free Flap for Oral Cavity/Oropharyngeal Reconstruction to Limit Donor Site Sequelae

An interventional study of Oropharyngeal or oral cavity reconstruction in Head and Neck Cancer, Oral Cavity Cancer and Oropharynx Cancer, sponsored by Institut Claudius Regaud. Recruiting at 4 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.

Primary conditionOropharyngeal NeoplasmsRegistry: Head and Neck NeoplasmsReclassifiedWhy we changed it
Registry
Head and Neck Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Oropharyngeal Neoplasms
Why
  1. The study's listed conditions name Oropharyngeal Neoplasms, a narrower term within Head and Neck Neoplasms.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Institut Claudius Regaud · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started Nov 2023; still recruiting 3 years later.
Updated Nov 18, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 31 studies in Oropharyngeal Neoplasms with a site in France — 7 open to participants now, 9 under way, 4 of them phase 3. Oropharyngeal Neoplasms · France.

Planned enrollment
19th of 22
40 · median 116
Started
2023
the only one that year
No phase
9 of 31
3 open now
Registered
24th of 31
by date

Among the 31 studies in Oropharyngeal Neoplasms with a site in France, this one is the 19th largest by planned enrollment of the 22 interventional ones that give a count, is the only one that started in 2023, is one of 9 with no phase, and was the 24th registered.

Oropharyngeal Neoplasms

370 studies on the registry are indexed under Oropharyngeal Neoplasms; 104 are open to participants now.

Browse Oropharyngeal Neoplasms studies →

Open to participants now

7 of the 31 studies in Oropharyngeal Neoplasms with a site in France are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 89 Oropharyngeal Neoplasms studies recruiting now, 76 (85%) set no upper age limit and 5 (6%) stop at 75 or younger; none take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Oropharyngeal Neoplasms with a site in France, or all of them as a file.
02

Study summary

This is a phase 1b, multicenter, non-randomized prospective study involving an innovation phase (IDEAL-1) followed by a prospective development phase (IDEAL-2A) designed to evaluate the safety and feasibility of oral/oropharyngeal reconstruction with the external pudendal free flap in two groups of patients.

A maximum of 40 patients (20 patients per group) will be included in this IDEAL-1/2A phase study.

Stage IDEAL-1: Innovation phase. The main objective is to evaluate the feasibility in terms of limiting surgical complications of a STEPA flap reconstruction in two groups of patients (Cohort: Male, Female).

Stage IDEAL-2A: Prospective development phase. The main objective is to describe the complication profile of the surgical procedure in these two patient populations.

Each patient will be followed during 12 months after the end of complete treatment (surgery ± adjuvant treatment).

A complementary study (observational study) of 250 patients will also be conducted to evaluate the acceptability of the technique (reconstruction by external pudendal flap) by the patients and to describe the factors associated with this acceptability.

03

Conditions studied

  • Head and Neck Cancer
  • Oral Cavity Cancer
  • Oropharynx Cancer

Browse trials for

Keywords

  • Head and Neck Cancer
  • Oral Cavity Cancer
  • Oropharynx Cancer
  • STEPA flap
  • Oropharyngeal or oral cavity reconstruction
  • IDEAL Recommendations
04

In context

Oropharyngeal Neoplasms Reclassified

370 studies on the registry are indexed under Oropharyngeal Neoplasms; 104 are open to participants now.

This study's planned enrollment of 40 is below the median of 52 across 265 interventional studies indexed under Oropharyngeal Neoplasms.

Browse Oropharyngeal Neoplasms studies →

Lead sponsor

Institut Claudius Regaud is the lead sponsor of 117 studies on the registry; 32 are open to participants now.

Compared within Oropharyngeal Neoplasms, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Head and Neck Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient with a proven diagnosis of head and neck squamous cell carcinoma (HNSCC) of the oral cavity or oropharynx.
  2. Patient whose disease is classified UICC TNM stade (8th edition) : T0-4a N0/N2c M0 (no distant M0).
  3. Patient whose oral cavity or oropharynx reconstruction requires a free fasciocutaneous flap according to an experienced oncology surgeon.
  4. Patient OMS 0-1.
  5. Age ≥ 18.
  6. Patient with no to surgery.
  7. Patient affiliated to a Social Health Insurance in France.
  8. Patient able to participate and willing to give prior performance of any study-related procedures and to comply with the study protocol.

Exclusion criteria

Exclusion Criteria:

  1. Patient with history of prior cervical surgery and/or radiation to the head and neck.
  2. History of pelvic surgery and/or radiation to the pelvic area.
  3. Patients with a to any form of sedation.
  4. Patient with irreversible coagulopathy.
  5. Patient with a contraindication to a CT scan or an injection of iodinated contrast medium.
  6. Patient with active disorders requiring therapy, defined as receiving (dose > 10 mg of prednisone or equivalent) or other immunosuppressive therapy.
  7. Pregnant or breastfeeding women.
  8. Patient with another co-existing at the time of inclusion or any other significant medical, psychiatric, or surgical condition currently not controlled by treatment, which may interfere with the conduct of the study.
  9. Patient with diabetes (type 1 or 2).
  10. Patient with a > 30kg/m².
  11. Any psychological, family, geographic or sociological condition that does not allow for compliance with the medical follow-up and/or procedures provided for in the study protocol .
  12. Patient who has forfeited his/her freedom by administrative or legal award or who is under legal protection (curatorship and guardianship, protection of justice).
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

06

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Patient with an ORL Cancer

    Procedure: Oropharyngeal or oral cavity reconstruction

Interventions

  • ProcedureOropharyngeal or oral cavity reconstruction

    Oropharyngeal or oral cavity reconstruction will be performed using a free super thin external pudendal artery flap (STEPA flap). Post-operative follow-up and adjuvant treatment: Post-operative follow-up of patients will be performed according to the standards of the participating centers.

07

What researchers measure

Primary outcomes

  1. The occurrence of a limiting complication. Limiting complications are defined as total flap necrosis (flap failure) or donor site infection (Fournier Gangrene) within 4 weeks of the experimental procedure.

    Time frame: 4 weeks for each patient

Secondary outcomes

  1. The postoperative complications will be evaluated according to the NCI-CTCAE version n°5

    Time frame: 12 months for each patient

  2. The pain will be assessed according to a Likert scale between 0 (no pain) and 10 (worst pain).

    Time frame: 12 months for each patient

  3. The functional capacity of swallowing will be assessed via the Performance Status Scale for Head and Neck cancer patients - PSS-HN (Scales are: Normalcy of Diet, Public Eating, and Understandability of Speech).

    Time frame: 12 months for each patient

  4. 4. The aesthetic evaluation will be performed according to a Likert scale (Likert scale: not at all satisfied, somewhat not satisfied, neither dissatisfied nor satisfied, somewhat satisfied, very satisfied).

    Time frame: 12 months for each patient

08

Study locations

2 of 4 sites recruiting
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2023 (actual). Primary completion is estimated for May 2028, 54 months after the start.

Of 52 non-industry interventional studies with no phase under Oropharyngeal Neoplasms, half reached primary completion within 78 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 116. This study's planned 54 months is below that.

Counting every sponsor, half of 54 studies reached it within 78 months; a quarter within 27 and three quarters within 153.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 18, 2026: primary completion May 2026 → May 2028 and completion Jan 2027 → Aug 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 24, 2023
First posted
Mar 7, 2023
StartActual
Nov 8, 2023
Primary completionEst.
May 2028was May 2026
CompletionEst.
Aug 2029was Jan 2027
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
May 2026→May 2028
Nov 18, 2026
Study completion
Jan 2027→Aug 2029
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    Primary completion May 2026→May 2028
    Study completion Jan 2027→Aug 2029
    + 2 other changes: verification date and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05757817
Responsible party
Sponsor
First posted
Mar 7, 2023
Start date
Nov 8, 2023
Primary completion
May 2028 (estimated)
Completion
Aug 2029 (estimated)
Last update
Nov 18, 2026

Study contacts

Agnès DUPRET-BORIES
Contact
dupret-bories.agnes@iuct-oncopole.fr
05 31 15 53 08

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion